This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (38) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Parrott, A. C. Search for Related Content PubMed PubMed Citation Articles by Parrott, A. C. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB 3,4-METHYLENEDIOXYMETHAMPHETAMINE Medline Plus Health Information Club Drugs Drug Abuse Social Bookmarking                         What's this?

Chronic tolerance to recreational MDMA (3,4-methylenedioxymethamphetamine) or Ecstasy

Department of Psychology, University of Wales, Swansea, UK, a.c.parrott{at}swansea.ac.uk

This review of chronic tolerance to MDMA (3,4-methylenedioxymetamphetamine) covers the empirical data on dosage escalation, reduced subjective efficacy and bingeing in recreational Ecstasy users. Novice users generally take a single Ecstasy tablet, regular users typically take 2-3 tablets, whereas the most experienced users may take 10-25 tablets in a single session. Reduced subjective efficacy following repeated usage is typically described, with many users subjectively reporting the development of tolerance. Intensive self-administration or bingeing is often noted by experienced users. This can comprise ‘stacking’ on several tablets together, and ‘boosting’ on successive doses over an extended period. Some experienced users snort Ecstasy powder nasally, whereas a small minority inject MDMA. Chronic tolerance and bingeing are statistically linked to higher rates of drug-related psychobiological problems. In terms of underlying mechanisms, neuroadaptive processes are certainly involved, but there is a paucity of evidence on hepatic and behavioural mechanisms. Further studies specifically designed to investigate chronic tolerance, involving low intermittent dose regimens, are required. Most animal research has involved intensive MDMA dosing regimens designed to engender serotonergic neurotoxicity, and this may comprise another underlying mechanism. If distal serotonin axon terminal loss was also developing in recreational users, it may help to explain why reducing subjective efficacy, dosage escalation and increasing psychobiological problems often develop in parallel. In conclusion, there is extensive evidence for chronic pharmacodynamic tolerance to recreational Ecstasy/MDMA, but the underlying mechanisms are currently unclear. Several traditional processes are probably involved, but one of the possible causes is a novel mechanism largely unique to the ring substituted amphetamine derivatives, namely serotonergic neurotoxicity.

Key Words: Ecstasy • MDMA • neurotoxicity • pharmacodynamic • pharmacokinetic • serotonin • tolerance

Journal of Psychopharmacology, Vol. 19, No. 1, 71-83 (2005)
DOI: 10.1177/0269881105048900


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. H. Baumann, D. Zolkowska, I. Kim, K. B. Scheidweiler, R. B. Rothman, and M. A. Huestis Effects of Dose and Route of Administration on Pharmacokinetics of ({+/-})-3,4-Methylenedioxymethamphetamine in the Rat Drug Metab. Dispos., November 1, 2009; 37(11): 2163 - 2170. [Abstract] [Full Text] [PDF]

				A. C. Parrott Ecstasy versus alcohol: Tolstoy and the variations of unhappiness J Psychopharmacol, January 1, 2007; 21(1): 3 - 6. [PDF]

				B. J. Piper, H. L. Vu, M. G. Safain, A. J. Oliver, and J. S. Meyer Repeated Adolescent 3,4-Methylenedioxymethamphetamine (MDMA) Exposure in Rats Attenuates the Effects of a Subsequent Challenge with MDMA or a 5-Hydroxytryptamine1A Receptor Agonist J. Pharmacol. Exp. Ther., May 1, 2006; 317(2): 838 - 849. [Abstract] [Full Text] [PDF]

				A. C. Parrott MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress J Psychopharmacol, March 1, 2006; 20(2): 147 - 163. [Abstract] [PDF]

				R. Thomasius, P. Zapletalova, K. Petersen, R. Buchert, B. Andresen, L. Wartberg, B. Nebeling, and A. Schmoldt Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective J Psychopharmacol, March 1, 2006; 20(2): 211 - 225. [Abstract] [PDF]

				J. P. Capela, A. Meisel, A. R. Abreu, P. S. Branco, L. M. Ferreira, A. M. Lobo, F. Remiao, M. L. Bastos, and F. Carvalho Neurotoxicity of Ecstasy Metabolites in Rat Cortical Neurons, and Influence of Hyperthermia J. Pharmacol. Exp. Ther., January 1, 2006; 316(1): 53 - 61. [Abstract] [Full Text] [PDF]